In fact, in combination with other clinical parameters PSA helps to predict locally advanced or metastatic disease (Sands et al, 1994; Partin et al, 1997; Cagiannos et al, 2003), whereas limited information is available to predict failure after specific therapy, possibly guiding high-risk patients into tailored follow-up protocols (Pound et al, 1999; Kattan et al, 2001). The gene discussed is KLK3; the disease is metastatic neoplasm.